# EDGAR Filing Document

**Accession Number:** 0001567264
**File Stem:** 0001213900-23-005670
**Filing Date:** 2023-1
**Character Count:** 3409
**Document Hash:** 22508ef90871adef720a39bf59873bc7
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-23-005670.hdr.sgml**: 20230728

**ACCESSION NUMBER**: 0001213900-23-005670

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20230127

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** INTENSITY THERAPEUTICS, INC.
- **CENTRAL INDEX KEY:** 0001567264
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 461488089
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 61 WILTON ROAD, 3RD FLOOR
- **CITY:** WESTPORT
- **STATE:** CT
- **ZIP:** 06880
- **BUSINESS PHONE:** 203-221-7381

**MAIL ADDRESS:**
- **STREET 1:** 61 WILTON ROAD, 3RD FLOOR
- **CITY:** WESTPORT
- **STATE:** CT
- **ZIP:** 06880

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Intensity Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20130117

---

| | |
|:---|:---|
| ![](image_001.jpg) | **mwe.com** |

---

January 27, 2023

**<u>VIA EDGAR AND EMAIL</u>**

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Attention: Jane Park <br> Christopher Edwards Sasha Parikh Al Pavot

---

| | |
|:---|:---|
| **Re:** | **Intensity Therapeutics, Inc.**<br> **Amendment No. 11 to Registration Statement on Form S-1**<br> **Filed January 13, 2023**<br> **File No. 333-260565** |

---

Dear Ms. Park:

On behalf of Intensity Therapeutics, Inc., a Delaware corporation (the "**Company**"), we are responding to the comments from the Staff (the "**Staff**") of the Securities and Exchange Commission (the "**Commission**") dated January 23, 2023 (the "**Comment Letter**"), relating to the above referenced Registration Statement on Form S-1 (File No. 333-260565) filed by the Company on January 13, 2023 (the "**Registration Statement**"). In response to the comments set forth in the Comment Letter, the Company has revised the Registration Statement and is filing it with the Commission together with its submission of this response letter. Set forth below is the Company's response to the Staff's comments. For convenience, the Staff's comments are repeated below in bold, followed by the Company's response.

<u>Amendment No. 11 to Form S-1 filed January 13, 2023</u>

<u>Our Strengths, page 54</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. **Please expand your discussion to describe the grade 3 and 4 adverse events in your IT-01 study and quantify the number of each type of event, as well as all other serious adverse events. Make similar revisions throughout your document, including in the discussion of your results, to identify all serious adverse events and quantify the number of each type of event.** 

<u>Response</u>: In response to the Staff's comment, the Company has revised its disclosure on pages 1, 55, 56, 65, 66, 67 and 76 of the revised Registration Statement to expand its disclosure of adverse events in its IT-01 study, including quantifying the number of each type of event.

Please contact me at +1 212 547 5553 if you have any questions or require any additional information in connection with this letter or the Company's submission of its revised Registration Statement on Form S-1.

---

| |
|:---|
| Sincerely, |
| */s/ Daniel Woodard* |
| cc: Lewis Bender, Chief Executive Officer |

---